Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

Anoro Ellipta side effects Anoro Ellipta can cause mild or serious side effects. The following lists contain some of the key side effects that may occur while taking Anoro Ellipta. These lists do not ...

GSK study demonstrates superiority of Anoro Ellipta to Stiolto Respimat in improving lung function in chronic obstructive pulmonary disease GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc.

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 17, 2014) - Theravance, Inc. (NASDAQ: THRX) -- Respiratory Medicine has published positive ...

The U.S. Food and Drug Administration have approved GlaxoSmithKline’s Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive ...

Theravance (THRX) says the FDA's Pulmonary-Allergy Drugs Advisory Committee will discuss the company's NDA for the COPD treatment Anoro Ellipta on September 10. (PR) Shares +1.5% AH.

LONDON, UK, 19 December, 2013 - Skyepharma PLC (LSE SKP),the expert oral and inhalation drug delivery company, today announces that the U.S. Food and Drug Administration ("FDA") has approved the New ...